WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, August 30, 2006, 26(35):9022-9029; doi:10.1523/JNEUROSCI.5216-05.2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (38)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prickaerts, J.
Right arrow Articles by Steckler, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prickaerts, J.
Right arrow Articles by Steckler, T.

 Previous Article  |  Next Article 

Behavioral/Systems/Cognitive
Transgenic Mice Overexpressing Glycogen Synthase Kinase 3beta: A Putative Model of Hyperactivity and Mania

Jos Prickaerts,1,3 * Dieder Moechars,2 * Kim Cryns,2 Ilse Lenaerts,1 Hansfried van Craenendonck,1 Ilse Goris,2 Guy Daneels,2 J. Adriaan Bouwknecht,1 and Thomas Steckler1

1Division of Psychiatry and 2Functional Genomics, Johnson & Johnson Pharmaceutical Research and Development, B-2340 Beerse, Belgium, and 3Department of Psychiatry and Neuropsychology, Maastricht University, 6200 MD, Maastricht, The Netherlands

Correspondence should be addressed to Dr. Thomas Steckler, Division of Psychiatry, Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, B-2340 Beerse, Belgium. Email: tsteckle{at}prdbe.jnj.com

Lithium is used as treatment for bipolar disorder with particular efficacy in the treatment of mania. Lithium inhibits glycogen synthase kinase 3beta (GSK-3beta) directly or indirectly via stimulation of the kinase Akt-1. We therefore investigated the possibility that transgenic mice overexpressing GSK-3beta could be of relevance to model bipolar disorder. Transgenic mice showed hypophagia, an increased general locomotor activity, and decreased habituation as assessed in an open field, an increased acoustic startle response, and again decreased habituation. The forced swim test revealed a reduced immobility in transgenic mice, but this is probably related to the hyperactivity of the animals. There were no differences in baseline and stress-induced increases of plasma adrenocorticotrophic hormone and corticosterone levels. Molecular analysis suggests compensatory mechanisms in the striatum of these transgenic mice for the overload of active GSK-3beta by dimming the endogenous GSK-3beta signaling pathway via upregulation of Akt-1 expression. Brain-derived neurotrophic factor protein levels were increased in the hippocampus of the transgenic mice. This suggests some kind of compensatory mechanism to the observed reduction in brain weight, which has been related previously to a reduced size of the somatodendritic compartment. Together, in mice overexpressing GSK-3beta, specific intracellular signaling pathways are affected, which is accompanied by altered plasticity processes and increased activity and reactivity, whereas habituation processes seem to be decreased. The behavioral observations led to the suggestion that the model at hand recapitulates hyperactivity as observed in the manic phase of bipolar disorder.

Key words: Akt-1; mania; lithium; bipolar disorder; schizophrenia; dopamine


Received Dec. 7, 2005; revised July 7, 2006; accepted July 28, 2006.

Correspondence should be addressed to Dr. Thomas Steckler, Division of Psychiatry, Johnson & Johnson Pharmaceutical Research and Development, Turnhoutseweg 30, B-2340 Beerse, Belgium. Email: tsteckle{at}prdbe.jnj.com




This article has been cited by other articles:


Home page
Schizophr BullHome page
M. van den Buuse
Modeling the Positive Symptoms of Schizophrenia in Genetically Modified Mice: Pharmacology and Methodology Aspects
Schizophr Bull, November 9, 2009; (2009) sbp132v1.
[Abstract] [Full Text] [PDF]


Home page
DMMHome page
O. Malkesman, D. R. Austin, G. Chen, and H. K. Manji
Reverse translational strategies for developing animal models of bipolar disorder
Dis. Model. Mech., May 1, 2009; 2(5-6): 238 - 245.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
J.-M. Beaulieu and M. G. Caron
Looking at Lithium: Molecular Moods and Complex Behaviour
Mol. Interv., October 1, 2008; 8(5): 230 - 241.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
B. Masri, A. Salahpour, M. Didriksen, V. Ghisi, J.-M. Beaulieu, R. R. Gainetdinov, and M. G. Caron
Antagonism of dopamine D2 receptor/{beta}-arrestin 2 interaction is a common property of clinically effective antipsychotics
PNAS, September 9, 2008; 105(36): 13656 - 13661.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. P. Fernandez, J. Serrano, L. Tessarollo, F. Cuttitta, and A. Martinez
Lack of adrenomedullin in the mouse brain results in behavioral changes, anxiety, and lower survival under stress conditions
PNAS, August 26, 2008; 105(34): 12581 - 12586.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
F. W. Wolf, M. Eddison, S. Lee, W. Cho, and U. Heberlein
GSK-3/Shaggy regulates olfactory habituation in Drosophila
PNAS, March 13, 2007; 104(11): 4653 - 4657.
[Abstract] [Full Text] [PDF]


Home page
Cold Spring Harb Symp Quant BiolHome page
C. A. McClung
Role for the Clock Gene in Bipolar Disorder
Cold Spring Harb Symp Quant Biol, January 1, 2007; 72(0): 637 - 644.
[Abstract] [PDF]



-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-